The mouse hepatitis virus (MHV) spike glycoprotein mediates attachment of the virus to the MHV receptor, the murine biliary glycoprotein (BGP) carcinoembryonic antigen. Monoclonal antibody CC1 directed against BGP specifically inhibited infection of DBT, Sac-, GT1-7, and OBL21 cells by wild-type MHV-4 and the neuron-adapted variant OBLV60. Binding to this receptor was necessary to establish infection by cell-free MHV; however, the presence of BGP was not required for infection by cell-associated virus. Cell-associated infection induced syncytium formation on Vero and BHK cells, which lack murine BGP; this activity was not inhibited by monoclonal antibody CC1. Antibody CC1 also did not prevent syncytium formation on DBT cells, which bear BGP. In infectious center assays, the MHV-4 variant OBLV60, which exhibits acid-dependent fusion, spread to cells lacking BGP only when exposed to acidic media. Therefore, spike-mediated fusion was required for BGP-independent spread of MHV infection. Furthermore, BGP-independent, cell-associated spread of MHV-4 was prevented by monoclonal antibodies 5A13.5 and 5B19.2 directed against the spike glycoprotein, but not by other neutralizing and nonneutralizing anti-spike antibodies. Expression of spike glycoprotein by recombinant vaccinia virus resulted in fusion of BGP-negative cells; monoclonal antibodies 5A13.5 and 5B19.2 strongly inhibited spike-mediated fusion in this assay.
INTRODUCTION
likely contains the receptor-binding domain. The carboxyterminal S2 portion of S is anchored in the viral memVirus infection of cells is initiated through the interacbrane by a hydrophobic transmembrane domain. Heptad tion of one or more virion components with receptor molrepeat sequences in S2 are thought to fold into a-helices ecules on the cell surface. Cellular receptors have been that associate with one another in a coiled coil, forming identified for several viruses and the specificity and affinthe stalk of the oligomeric peplomer (de Groot et al., ity of the virus-receptor interaction can dictate the 1987). In contrast to the fusion proteins of several other course of infection in vivo. The tissue distribution and enveloped RNA viruses, cleavage of the murine coronaviavailability of receptors are primary determinants of viral rus spike glycoprotein does not unmask an apparent tropism and influence viral pathogenesis. Subsequent to N-terminal hydrophobic fusion peptide. The S2 heptad receptor binding, viruses enter the cell through fusion repeat region has, however, been shown to contain resieither at the plasma membrane or in endosomal vesicles.
dues that influence the pH dependence of fusion (GalInternalization of virus may also be facilitated by addilagher et al., 1991) . tional low or high affinity interactions between virion proThe receptors for mouse hepatitis virus (MHV) are teins and cell surface molecules (Fuller and Spear, 1987;  members of the murine biliary glycoprotein family (BGP), Weiss, 1992; Wickham et al., 1993) .
which are carcinoembryonic antigens (CEA) in the immuThe coronaviruses share in common a virion structure noglobulin superfamily . Two marked by distinctive peplomers that extend 200 Å from murine bgp genes have been characterized, bgp1 and the surface of the virion (Sturman et al., 1980) . The bgp2 (Nedellec et al., 1994) . Through stable or transient peplomer comprises a homotrimer of spike (S) glycoproexpression of transfected cDNA, four isoforms of BGP1 teins (Delmas and Laude, 1990 ) and mediates both virus and one isoform of BGP2 have been shown to render attachment and membrane fusion. Glycoprotein S is a resistant cells susceptible to infection by MHV (Dveksler 180-kDa class I integral membrane protein that is postet al., 1991 Yokomori and Lai, 1992a ; Nedellec et translationally cleaved into two 90-kDa fragments called al., 1994) ; however, in some cases an additional cellular S1 and S2 (Sturman et al., 1985) . The amino-terminal S1
factor may be necessary for viral entry (Yokomori and portion forms the globular head of the peplomer and Lai, 1992b; Yokomori et al., 1993) . The N-terminal domain of BGP, which displays additional polymorphism due to attachment, and thereby inhibit infection of cultured fibroborn CD1 mice (Ryder et al., 1990) , and GT1-7, a murine hypothalamic neuronal cell line (Mellon et al., 1990) , were blasts Dveksler et al., 1991 Dveksler et al., , 1993 . A CEA molecule in the pregnancy-specific glycoprotein maintained in DMEM/10% fetal bovine serum. All media solutions were supplemented with 25 mM HEPES and 2 subgroup can also serve as a receptor for some strains of MHV, but not for the neurotropic MHV-4 (JHM) strain mM L-glutamine. (Chen et al., 1995) . Virus It has been demonstrated previously that the presence of BGP (formerly called CEA-related MHV receptor) is
The MHV-4 strain of virus was originally obtained from not required for cell-to-cell spread of MHV-4 infection M. Haspel (Haspel et al., 1978) and is routinely passaged (Gallagher et al., 1992) . Cells lacking BGP were producin Sac-cells. The OBLV60 variant was isolated on Day tively infected through fusion into virus-induced syncytia.
60 of a persistent MHV-4 infection established in OBL21a Cell fusion was shown to be mediated by the spike glycocells (Gallagher et al., 1991) . protein. Specifically, MHV syncytia developed on monolayers of BHK and RK13 cells when these cells were Antibodies cocultured with small numbers of monodispersed MHV-
The generation and characterization of monoclonal infected DBT cells. BHK cells are resistant to MHV infecantibodies against MHV-4 and the production of ascites tion, but BHK cells transfected with BGP supported MHV fluid has been previously described (Collins et al., 1982; infection (Dveksler et al., 1991) , indicating that BHK cells Buchmeier et al., 1984) . The specificity of the monoclonal possess all of the components required for MHV replicaantibodies against the nucleocapsid (N), membrane (M), tion except the receptor. The cell-associated spread of or S proteins are as follows: 4B6.2 (N), 5A5.2 (M), 5B11.2 infection to the BGP-negative BHK and RK13 cells led to (M), 5A13.5 (S), 5B19.2 (S), 4B11.6 (S), 5B93.3 (S), 5B21.5 the production of 250 and 21 times more infectious virus, (S), 5B207.7 (S), and 5B216.8 (S). Monoclonal antibody 1-respectively, than duplicate cultures without a target cell 1.3 recognizing the lymphocytic choriomeningitis virus monolayer (Gallagher et al., 1992) . Therefore, through (LCMV) nucleocapsid protein was used as a control anticell-to-cell spread of infection, MHV can bypass the rebody against an unrelated antigen (Buchmeier et al., ceptor-binding event normally required for extracellular 1981). Anti-BGP antibody CC1 hybridoma supernatant infection.
was generously provided by Kathryn Holmes. In this report, we examined the receptor utilization by the neurotropic strain MHV-4 and a neuron-adapted variPlaque assays ant, OBLV60, in cultured cells of neuronal and nonneuronal origin. We demonstrate that although anti-BGP antiViral titers were determined by plaque assay in which DBT cell monolayers in six-well culture plates were inocbody CC1 prevents MHV-4 and OBLV60 infection of several cell types, it does not block cell-associated spread ulated with serial log or half-log dilutions of virus. After a 1-hr absorption period, the inoculum was removed and of infection. This finding supports our contention that the cell-associated spread of MHV does not require the replaced with overlay medium (DMEM, 1% calf serum, 0.5% SeaKem agarose). After plaque development, the presence of BGP. Further, we investigated the role of spike-mediated fusion in BGP-independent, cell-associmonolayers were fixed with Ç5% paraformaldehyde, then stained with 0.1% crystal violet after removal of the agaated MHV infection and found that this alternate mechanism of spread requires spike-mediated fusion activity. rose overlay.
To quantitate the capacity for anti-BGP antibody CC1 We used vaccinia-based expression of spike glycoprotein to assay fusion activity that is independent of recepto inhibit MHV-4 infection, plaque reduction assays were performed as follows. DBT or Sac-cell monolayers in tor interaction and demonstrate that monoclonal antibodies which inhibit fusion also prevent BGP-independent, six-well culture plates were incubated with either no antibody or half-log dilutions of antibody CC1 for 1 hr before cell-associated spread of MHV infection. and 2 hr after infection with a standardized inoculum of MHV-4 (150 PFU). The inoculum was then removed and MATERIALS AND METHODS replaced with overlay medium. Fixation and staining Cells were performed as described above. The ability of antibody CC1 to inhibit infection with MHV-4 or OBLV60 was DBT murine astrocytoma (Hirano et al., 1978) and SacMoloney sarcoma (Weiland et al., 1978) cell lines were also assessed microscopically. Confluent monolayers of GT1-7, OBL21, DBT, or Sac-cells were pretreated for 1 maintained in DMEM with 8% calf serum (Hyclone). BHK-21 cells (baby hamster kidney) were maintained in hr at 37Њ with antibody CC1 at twice the dilution indicated, before addition of an equal volume of virus. After 16 to DMEM/8% calf serum with 0.11 TPB and 0.5% glucose. Vero E6 cells (African green monkey kidney) were main-20 hr of incubation at 37Њ, cells were fixed and processed for immunofluorescence. tained in MEM/10% fetal bovine serum (Irvine Scientific) with 0.25% NaHCO 3 . OBL21, a retrovirus-transformed
The neutralizing titer of ascites fluid containing monoclonal antibody against MHV-4 was quantitated by neuronal cell line derived from the olfactory bulb of new-plaque reduction assay as follows. Ascites fluids were serially diluted in DMEM and mixed with an equal volume (0.2 ml) of a standardized inoculum of MHV-4 (100 PFU). The virus-antibody mixtures were incubated at 4Њ for 1 hr, then used to inoculate DBT cell monolayers in sixwell culture plates. Following a 1-hr absorption at 37Њ, the inoculum was removed and replaced with overlay medium. Fixation and staining were performed as described above.
The capacity of ascites fluid to inhibit cell-cell fusion was quantitated by plaque reduction assay. DBT cell monolayers were incubated with a standardized inoculum of MHV-4 (100 PFU) for 1 hr at 37Њ. The inoculum was then removed and replaced with overlay medium containing ascites fluid at serial dilutions. Fixation and Lab-Tek chamber slides were fixed with 10% zinc-formalin for 5 min at room temperature, permeabilized with 2% NP-40 for 10 min, then blocked with 5% normal goat Expression of recombinant S glycoprotein serum (Vector Laboratories) for 15 min or more. The cells BHK or DBT cell monolayers grown on glass coverslips were bathed for 1 hr or more with a cocktail of anti-MHV were co-infected with the recombinant vaccinia virus enantibodies (4B6.2, 5A5.2, and 5B19.2 or 5A13.5, recognizcoding bacteriophage T7 RNA polymerase, vTF7.3 ing nucleocapsid, membrane, and spike proteins, re- (Fuerst et al., 1986) , and a recombinant vaccinia virus spectively) at a 1:100 dilution in phosphate-buffered that has the MHV-4 spike cDNA under the control of the saline (PBS) containing 1% normal goat serum, then incu-T7 RNA polymerase promoter (vv-S). The spike vaccinia bated for 1 hr with a TRITC-conjugated, sheep antirecombinant had been derived through homologous remouse antibody (Accurate), also diluted in PBS concombination between vaccinia DNA and MHV-4 spike taining 1% normal goat serum. Cells were mounted in cDNA inserted into the pTM-1 vector (T. M. Gallagher and 90% glycerol containing 25 mg/ml 1,4-diazobicyclo-2,2,2-M. J. Buchmeier, unpublished data, 1994) . Expression of octane in PBS and visualized by fluorescence microsrecombinant spike glycoprotein was detected by indirect copy.
immunofluorescence. For specified experiments, antispike monoclonal antibodies 5A13.5, 5B19.2, 4B11.6, Infectious center assay 5B93.3, 5B21.5, 5B207.7, or 5B216.8 or control antibodies directed against BGP (CC1), the membrane protein Adherent DBT cells were removed from tissue culture (5B11.5), nucleocapsid protein (4B6.2), or the LCMV nuflasks by treatment with Nonenzymatic Cell-Dissociation cleocapsid protein (1-1.3) were included at a 1:100 or Solution (Sigma) and infected with MHV-4 or OBLV60 in 1:500 dilution. suspension at a multiplicity of 5 PFU per cell. The cells were incubated at 37Њ for 1 hr, then washed extensively RESULTS in cold PBS or OptiMem serum-free medium (Gibco). The infected cells were serially diluted in OptiMem media Anti-BGP antibody CC1 inhibits both MHV-4 and containing monoclonal antibody CC1 (1:100 dilution), OBLV60 infection then seeded onto untreated glass coverslips or coverslips covered with confluent BHK, Vero, or DBT cell Dveksler et al. (1991) have demonstrated that BGP is a functional receptor for MHV strain A59 by inhibiting monolayers. All target cell monolayers had been pretreated with monoclonal antibody CC1 (1:50 dilution) for infection with the anti-BGP monoclonal antibody CC1. To confirm that the neurotropic MHV-4 strain also uses this 1 hr; a 1:100 dilution of antibody CC1 was present throughout the course of the experiment. For specified receptor, we performed receptor-blocking experiments with monoclonal antibody CC1. Figure 1 shows that antiexperiments, anti-spike monoclonal antibody 5A13.5, 5B19.2, 4B11.6, 5B93.3, or 5B21.5 was also included at body CC1 led to a reduction of MHV-4 plaque formation assayed on two different murine cell lines. Complete inhia 1:100 dilution. At 20 hr postinfection, the cells were fixed and infected cells were visualized by indirect immubition was measured at dilutions of antibody CC1 less than 10
02.5
. The 50% reduction in plaque number was nofluorescence. greater than 10 03.5 for antibody CC1 on both cell lines.
The ability of anti-BGP monoclonal antibody CC1 to inhibit infection with MHV-4 or OBLV60 was also asThe dose-dependent plaque reduction indicates that antibody CC1 blocks the MHV receptor that is utilized by sessed microscopically, in which case the extent of infection was visualized following indirect immunofluorescent MHV-4 in both DBT and Sac-cells. 72 staining of viral antigen. MHV infection of the neuronal supports the conclusion that cell-associated spread of MHV can occur without BGP serving as the MHV receptor. cell lines GT1-7 and OBL21 does not cause the formation of discernible plaques; however, there is clearly a doseSpike-mediated fusion is required for BGPdependent inhibition of MHV-4 and OBLV60 infection of independent cell-to-cell spread of MHV infection these cell lines by monoclonal antibody CC1. Representative examples in which confluent monolayers of these OBLV60 is a fusion variant of MHV-4 that arose during cells were inoculated with MHV-4 or OBLV60 with or persistent infection of the OBL21a cell line (Gallagher et without monoclonal antibody CC1 pretreatment are al., 1991) , a neuronal cell line that is refractory to MHVshown in Fig. 2. At a 10 02 dilution of antibody CC1, in induced cell fusion. Due to three amino acid mutations fields of more than 10 5 cells, no MHV-4-infected GT1-7 that occurred in the heptad repeat region of S2, the cells were detected (Fig. 2C) , and the number of OBLV60-OBLV60 spike glycoprotein requires acid activation in infected GT1-7 (Fig. 2F) or OBL21 (Fig. 2I ) cells detected order to mediate membrane fusion (Gallagher et al., was reduced by more than 50% compared to the corre-1991). Consequently, infection of fusion-sensitive cells sponding cultures without antibody CC1 (Figs. 2D and with OBLV60 leads to syncytium formation only in acidic 2G). At higher concentration of antibody CC1, only an culture medium. occasional OBLV60-infected GT1-7 (Fig. 2E) or OBL21
To assess the role of fusion in BGP-independent, cell- (Fig. 2H) cell was detected. Together, these results demassociated spread of MHV, we tested whether infection onstrate that infection of both neuronal and nonneuronal spreads in a BGP-independent manner from cells incells by cell-free MHV-4 and OBLV60 requires the presfected with the OBLV60 acid-dependent fusion variant. ence of accessible BGP.
An infectious center assay was performed in which OBLV60-infected DBT cells were seeded with (Figs. 3F Anti-BGP antibody CC1 does not prevent cell-to-cell and 3H) and without (Figs. 3E and 3G) an underlying spread of MHV infection monolayer of confluent BGP-negative BHK or Vero target cells. As above, monoclonal antibody CC1 was present Cell-associated spread of MHV to cells that lack murine throughout the course of the experiment. In neutral pH BGP has been demonstrated with an infectious center culture medium, OBLV60 infection remained isolated to assay in which infection spread from MHV-infected DBT the single cells of the overlay and failed to spread to cells to BGP-negative target cell monolayers (Gallagher et receptor-negative target cells (Fig. 3F) . However, when al., 1992). To further test the role of BGP in cell-associated exposed to acidic (pH 5.0) medium for 1 hr, small syncytia spread of MHV infection, infectious center assays were developed as a result of one round of fusion between performed with inclusion of the receptor-blocking monothe OBLV60-infected cells and adjacent BGP-negative clonal antibody CC1 in the culture media. Confluent BHK, cells; return to neutral pH prevented the further spread Vero, and DBT cell monolayers were preincubated with of infection. The ability of the OBLV60 fusion variant to antibody CC1 for 1 hr, then overlaid with a suspension of spread to BGP-negative cells only at acidic pH demon-MHV-4-infected DBT cells. At 20 hr postinfection, infected strates that spike glycoprotein fusion capability is re-DBT cells plated without an underlying monolayer were quired for BGP-independent, cell-associated spread of widely dispersed and remained single cells (Figs. 3A and MHV infection. 3C), whereas large syncytia were evident in the cultures with BHK (Fig. 3B) , DBT (Fig. 3D ), or Vero (data not shown)
BGP-independent, cell-associated spread of MHV-4 is target cell monolayers. The number of syncytia was approxprevented by fusion-inhibiting anti-spike monoclonal imately equal to the number of infected single cells in the antibodies cultures without an underlying monolayer (data not shown), consistent with a cell-to-cell rather than extracellular mode
We have previously reported the generation and characterization of a panel of neutralizing and nonneutralizing of virus transmission. The presence of syncytia indicates that infection spread from the primary infected DBT cells monoclonal antibodies directed against the MHV-4 spike glycoprotein (Collins et al., 1982; Buchmeier et al., 1984) . to the BHK, Vero, and DBT cell monolayers, despite the presence of antibody CC1 in the culture medium. The inabil-
The results of plaque reduction assays quantitating the neutralization and fusion inhibition titers for monoclonal ity of monoclonal antibody CC1 to prevent infection of target cell monolayers in these infectious center assays further antibody ascites preparations used in this study are 5B207.7 (0%) did not prevent fusion (Fig. 4B) . The plaques were significantly smaller than normal in the assays with a Antibody dilutions 1:100; PRA, plaque-reduction assay; vv-S, vaccinia virus-expressed spike glycoprotein; BGP-IS, BGP-independent antibody 5A13.5 at all dilutions, or antibodies 5B19.2 or spread; ND, not determined.
4B11.6 at dilutions of 10 02 , 10 02.5 , and 10 03 .
b Buchmeier et al., 1984. To examine the structural and functional features of c Small plaque morphology.
the spike glycoprotein that are important for receptorindependent syncytia formation, we tested the ability of anti-spike monoclonal antibodies to interfere with BGPindependent spread of MHV-4 infection in an infectious center assay. MHV-4-infected DBT cells were bathed in media containing individual anti-spike monoclonal antibodies (1:100 dilution) before being seeded onto confluent BHK cell monolayers. Both anti-spike monoclonal antibodies and anti-receptor antibody CC1 were present at a 1:100 dilution throughout the course of the experiment. Two antibodies, 5A13.5 and 5B19.2, routinely prevented MHV-induced syncytia formation; infectious centers remained mononuclear (Figs. 5B and 5C ). Monoclonal antibody 4B11.6 inhibited, but did not consistently prevent BGP-independent spread of MHV-4. In some experiments, a few small syncytia were detected in the presence of antibody 4B11.6; however, most infectious centers remained mononuclear (Fig. 5D) . Monoclonal antibodies 5B93.3 and 5B21.5 had no apparent effect on BGP-independent spread of MHV-4. In the presence of antibodies 5B93.3 (Fig. 5E ) or 5B21.5 (Fig. 5F ), cell-cell fusion led to the formation of syncytia that were approximately the same size at the syncytia that developed in the absence of anti-spike monoclonal antibodies (Fig. 5A ) and no mononuclear infectious centers were detected.
Inhibition of recombinant spike-mediated fusion by anti-spike monoclonal antibodies MHV-induced fusion activity can be mediated by the spike glycoprotein alone; no other viral components are required (Pfleiderer et al., 1990; Gallagher et al., 1991) . We (Gallagher et al., 1992) and others (Taguchi et al., 1992) have demonstrated that expression of recombinant MHV antibody CC1 is included in the culture medium (data not shown). These results demonstrate that expression of reantibodies 5A13.5 or 5B19.2 were present; antibodies 5A13.5 or 5B19.2 inhibited spike-mediated fusion in this combinant spike glycoprotein in BGP-negative cells provides an assay for fusion that is independent of receptor assay at both 1:100 and 1:500 dilutions. Representative examples of vv-S-induced syncytia and fusion inhibition by interactions. Here, we used this assay to evaluate the capacity of anti-spike monoclonal antibodies to specifically antibody 5A13.5 are shown in Fig. 6 . In summary, BGP-independent spread of MHV-4 infecblock spike-mediated fusion.
BHK cells were co-infected with recombinant vaccinia tion was inhibited by anti-spike monoclonal antibodies that strongly inhibit MHV-induced syncytium formation viruses expressing T7 RNA polymerase (Fuerst et al., 1986) and the MHV-4 spike glycoprotein (vv-S) in the presence of and spike-mediated cell fusion, but not by neutralizing or nonneutralizing antibodies that do not inhibit fusion. 1:100 or 1:500 dilutions of the following antibodies: 5A13.5, 5B19.2, 4B11.6, 5B21.5, 5B93.3, 5B207.7, 5B216.8, 5B11.5 DISCUSSION (anti-M), 4B6.2 (anti-N), CC1 (anti-BGP), and 1-1.3 (anti-LCMV NP). Recombinant spike glycoprotein expression
We have demonstrated that cell-associated MHV can bypass the requirement for binding to its primary recepcaused syncytia formation in all cases tested except where tor, BGP, and thereby spread to cells that are resistant
We further demonstrated that BGP-independent, cellassociated spread of MHV requires viral fusion capabilto infection by cell-free MHV. Anti-BGP antibody CC1, which blocked infection by MHV virions, failed to prevent ity; the acid-dependent MHV fusion variant OBLV60 spread through a BGP-independent mechanism only uncell-associated spread of MHV to BGP-negative or BGPpositive cells. The capacity for BGP-independent, cellder conditions permissive for fusion. Viral fusogenicity is a function of the spike glycoprotein and expression of associated spread may permit greater dissemination of infection in vivo and consequently may augment virurecombinant spike glycoprotein alone is sufficient to induce syncytia formation. Recombinant MHV-4 spike glylence. We previously demonstrated that the MHV-4 strain, which is highly neurovirulent, spread to BGP-negacoprotein fused BGP-negative cells and was unaffected by anti-BGP antibody CC1; these results segregate the tive cells in culture more efficiently than the less neurovirulent A59 strain (Gallagher et al., 1992) ; however, these receptor-binding and fusion activities of the MHV spike glycoprotein. Theoretically, dissemination of MHV infectwo strains do differ significantly, particularly in the S1 domain of the spike glycoprotein, and therefore this obtion through a BGP-independent, cell-associated mechanism in vivo provides the potential for spread of infection servation does not conclusively demonstrate a correlation between neurovirulence and capacity for receptorto cells that lack BGP or despite the presence of neutralizing antibodies. Only anti-spike monoclonal antibodindependent spread. In an in vivo prophylaxis experiment, anti-BGP monoclonal antibody CC1 failed to fully ies 5A13.5 and 5B19.2 prevented BGP-independent, cellassociated spread of MHV infection. These antibodies protect infected mice against encephalitis (Smith et al., 1991) . The inability of anti-BGP antibody to completely strongly inhibited spike-mediated fusion in MHV plaque reduction assays and vaccinia-based expression experiprevent spread of infection to the brain is not surprising if a BGP-independent component of MHV spread operments. Interestingly, in vivo administration of these same two antibodies has been shown to attenuate MHV infecates in vivo. This alternate mechanism of spread may also explain how MHV, which does not infect primate tion and protect against fatal encephalitis in mice (Buchmeier et al., 1984) . A summary of the functional features fibroblasts in culture (Compton et al., 1992) , did infect primates inoculated with a suspension of infected murine of several anti-spike monoclonal antibodies is presented in Table 1 . cells or brain homogenate (Murray et al., 1992) .
Information about the structural domains of the spike known to be affected by the lipid composition of the plasma membrane (Daya et al., 1988; Roos et al., 1990) . glycoprotein recognized by the antibodies used in this study is limited. Monoclonal antibody 5B19.2 recognizes Other viruses that can mediate membrane fusion at neutral pH may also have the capacity to spread through a linear epitope (Luytjes et al., 1989) located in an immunodominant neutralization domain in a conserved region receptor-independent mechanisms. Interestingly, the fusogenic transmembrane protein of HIV, gp41, has been of S2 (Daniel et al., 1993) . Antibodies 5A13.5 and 4B11.6 recognize topographically distinct, conformation-depenreported to induce syncytium formation when expressed in cells normally resistant to infection with HIV virions, dent epitopes (Talbot et al., 1984) . Neuroattenuated MHV variants V5A13 and V4B11 (Dalziel et al., 1986) , which suggesting that receptor-independent, cell-associated spread may also occur during HIV infection (Perez et escaped neutralization by antibodies 5A13.5 and 4B116, respectively, have deletions in S1 (Parker et al., 1989; . The capability of viruses to bypass binding to primary receptors through, for example, the use of alter- Gallagher et al., 1990) ; however, it is not known whether the monoclonal antibody contact residues lie within the nate receptors or virus-mediated cell-cell fusion needs to be considered in the design of potential receptor-tardeleted region or whether the deletions affect protein conformation at other sites. Neutralization-resistant varigeted antiviral agents. ants with point mutations, rather than deletions, have also been isolated (Gallagher et al., 1990) ; we are cur-ACKNOWLEDGMENTS rently in the process of determining the nucleotide seWe thank Kirsten Gaarder, Martin Nackman, and Alyssa Paoletti quence of these variant spike genes in order to precisely for technical assistance and Kathryn Holmes for providing anti-BGP identify the 5A13.5 and 4B11.6 antibody epitopes.
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We propose two possible mechanisms for BGP-independent spread of MHV. First, the spike glycoprotein may be binding to an alternate, low-affinity receptor that is REFERENCES inadequate for initiating infection by virions. The pres-
